10.2.17 Lipids

Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5441_Библиотеки_им_академика_М_И_Перельмана.pdf

Скачиваний:

Добавлен:

10.10.2026

Размер:

9 Мб

Скачать

☆

<<< < Предыдущая 16 17 18 19 20 21 22 23 24 25 26 2728 / 4528 29 30 31 32 33 34 35 36 37 38 39 40 > Следующая >>>

260

blood glucose levels and providing energy to each of the body’s cells. This stimu-

lates metabolic processes and promotes overall healing, making it especially helpful

for those recuperating from surgery, trauma, or serious sickness. Dextrose is added

to LVPs to guarantee that patients get the critical carbohydrates needed to sustain

energy levels and important body processes. It is essential for maintaining stable

blood sugar levels, which is particularly critical for individuals who are unable to

swallow food or who have higher metabolic demands. Dextrose helps to meet

immediate energy needs, facilitating recovery and promoting overall health in clini-

cal settings where nutritional support via intravenous routes is necessary.

10.2.17 Lipids

Lipids, commonly known as fats, play essential roles in the body, serving as a con-

centrated source of energy, contributing to cell membrane structure, and aiding in

hormone production. In large volume parenterals (LVPs), lipid emulsions are

included to provide necessary nutrients that support overall health and recovery,

especially when oral or enteral feeding is not feasible.

Lipids in LVPs serve as a dense energy source, essential for patients needing

concentrated caloric intake during extended periods without oral nutrition or

increased energy demands due to illness or recovery. They also provide essential

fatty acids (EFAs) like omega-3 and omega-6, vital for cell membranes, brain func-

tion, inammation regulation, and heart health. Additionally, lipid emulsions deliver

fat-soluble vitamins (A, D, E, K), critical for immune function, vision, bone health,

clotting, and antioxidants, ensuring patients receive adequate levels for optimal

health and healing (Table10.4). In addition to energy and nutrient provision, lipids

support immune function and aid in recovery. They help maintain immune cell

integrity and function, contributing to the body’s ability to ght infections and pro-

mote healing.

10.3 Role andBenefits ofAdditives inLVPs

10.3.1 Nutritional Support

Large volume parenteral (LVP) additives are vital for supplying vital nutrients that

promote patient health and recuperation. They consist of lipids, vitamins, minerals,

amino acids, and carbs, all of which work synergistically to offer a balanced diet.

This is especially important for patients who are unable to consume enough nutri-

tion orally, such as those who are having surgery, are very sick, or have digestive

issues. LVPs contribute to the general well-being of patients by sustaining body

functioning and promoting healing through the intravenous delivery of vital

nutrients.

S. Shilpi et al.

261

10.3.2 Role of Parentral Admixture in Nutritional Deficiencies

LVP additives are also utilized to make up for deciencies that might result from

inadequate oral intake or certain medical concerns. For example, decits can be

addressed with supplements for vitamins like B12, which is essential for nerve

function, and minerals like zinc, which is critical for immunological health. This

adjustment is necessary to ensure good physiological functioning and avoid dif-

culties, particularly in individuals who have protracted hospital stays or chronic

diseases.

10.3.3 Therapeutic Benefits

Beyond basic nutrition, certain LVP additions have medicinal effects. Antioxidants

such as vitamin C, for instance, can reduce oxidative stress, which is benecial for

patients receiving rigorous therapy or suffering from infections. Amino acids pro-

mote immunological response and tissue repair, which help the body heal after sur-

gery or damage. These therapeutic benets improve overall recovery rates, facilitate

faster healing, and reduce complications, all of which improve patient outcomes.

Table 10.4 Admixtures in parenterals

Admixture

10.4.1.2 Aseptic Techniques

To avoid contamination and preserve sterility, aseptic procedures must be meticu-

lously followed while adding additives to LVPs. When preparing, a sterile environ-

ment should be employed, such as laminar ow hoods or isolators. Syringes,

needles, and vials retaining additives are just a few examples of sterile, parenterally

compatible equipment that have to be available. Using the proper personal protec-

tive equipment (PPE) can help reduce the danger of microbiological contamination

in personnel handling additives.

10.4.1.3 Dosing Considerations

Additives must be applied precisely in accordance with patient needs and recog-

nized dosage standards. This involves guring out the appropriate concentration

based on the patient’s weight, health, and dietary requirements. Insufcient or

excessive dosage may result in side effects or ineffective treatment results. Accuracy

and patient safety depend on pharmaceutical computations being double-checked

by trained personnel.

Concentration calculations ensure precise dosing for therapeutic efcacy and

safety in LVPs, considering patient specics and desired outcomes. Compatibility

checks prevent interactions that could compromise solution integrity, validated

through rigorous physical and chemical assessments. Ongoing training and compe-

tency assessments for personnel uphold dosing accuracy and adherence to safety

S. Shilpi et al.

263

protocols, ensuring consistent quality in clinical practice. Continuous education

updates healthcare providers on current standards and regulatory guidelines, pro-

moting patient safety and optimizing treatment outcomes.

10.4.1.4 Monitoring andDocumentation

Thorough documentation and monitoring are essential during the preparation phase.

Every stage, from choosing and preparing the additives to verifying the nished

product, needs to be well documented. Batch numbers, expiration dates, concentra-

tions, and any modications to normal operating procedures are all covered by this.

Quality control, traceability, and regulatory compliance are all supported by thor-

ough documentation.

10.5 Regulatory Considerations inLVP Preparation

10.5.1 Guidelines andStandards by Regulatory Authorities

Regulatory authorities such as the Food and Drug Administration (FDA) in the

United States and the European Medicines Agency (EMA) in Europe provide com-

prehensive guidelines and standards for the preparation of large volume parenterals

(LVPs). These guidelines aim to ensure the safety, efcacy, and quality of intrave-

nous therapies administered to patients.

10.5.1.1 FDA Guidelines

The FDA regulates LVPs under strict current Good Manufacturing Practice (cGMP)

guidelines, ensuring facilities, personnel, equipment, and processes comply with

stringent standards. Sterility assurance mandates controlled aseptic conditions to

prevent microbial contamination, requiring clean room environments and validated

sterilization methods. Quality control is paramount, involving rigorous testing of

raw materials, in-process samples, and nal products for identity, strength, purity,

and sterility. Proper labeling is crucial, with LVPs requiring clear details on con-

tents, dosage, expiration date, and storage conditions. Documentation must facili-

tate traceability, encompassing batch production records, testing outcomes, and

adverse event reports to uphold safety and regulatory compliance.

10.5.1.2 EMA Standards

In Europe, the EMA oversees LVPs under the regulatory frameworks of the

European Pharmacopoeia and EU GMP guidelines, which harmonize standards

internationally for consistency and compatibility. Compliance with the European

Pharmacopoeia specications ensures that LVPs meet stringent quality and safety

criteria.

The EMA mandates rigorous quality assurance akin to the FDA, including fre-

quent inspections of manufacturing facilities to uphold validated processes and pro-

cedures. This oversight ensures that LVPs consistently adhere to high-quality

standards throughout production. Comprehensive documentation is a cornerstone of

10 Sterile Products andAdmixtures

264

EMA regulations, encompassing detailed records of LVP manufacturing and test-

ing. Batch records, stability studies, and validation reports are meticulously main-

tained to demonstrate compliance with regulatory requirements. These

documentation practices support traceability and accountability, facilitating the safe

and reliable production of LVPs across European markets.

10.5.1.3 Quality Control andAssurance

Quality control in the production of large volume parenterals (LVPs) involves rigor-

ous testing and analysis of raw materials, in-process samples, and nal products to

verify adherence to specied standards. Tests cover aspects such as identity, strength,

purity, sterility, endotoxin levels, and the presence of particulate matter, ensuring

the integrity and safety of LVPs prior to patient administration. Concurrently, qual-

ity assurance oversees the entire quality management system, validating manufac-

turing processes, qualifying equipment, maintaining suitable facilities, and

providing ongoing training to personnel to uphold rigorous standards consistently.

These practices are crucial for mitigating risks, ensuring product consistency, and

safeguarding the efcacy and safety of LVPs throughout their production and distri-

bution cycles.

Stability testing is essential in the production of large volume parenterals (LVPs)

to assess their shelf life and optimal storage conditions. These studies evaluate the

product’s integrity and potency over time, considering environmental factors like

temperature, humidity, and light exposure that could affect stability. By subjecting

LVPs to controlled conditions mimicking real-world storage environments, manu-

facturers can predict how the product will behave over its intended shelf life. This

data informs decisions on storage recommendations, packaging materials, and expi-

ration dating, ensuring that LVPs maintain their quality and efcacy until they are

administered to patients. Stability testing thus plays a critical role in ensuring that

healthcare providers can rely on the consistency and reliability of LVPs throughout

their use in clinical settings.

10.5.1.4 Labeling andDocumentation Requirements

Accurate and thorough labeling and documentation are indispensable for ensuring

the safety and efcacy of large volume parenterals (LVPs). The labeling of LVPs

must contain essential information such as the product name, strength, dosage form,

route of administration, expiration date, and specic storage conditions. Clear and

concise handling instructions, along with any necessary warnings or precautions,

are also crucial to guide healthcare professionals in proper usage and patient safety.

Compliance with regulatory standards is essential to ensure that labels meet all

requirements, contributing to the overall quality assurance of the product.

Documentation for LVPs involves meticulous batch records that meticulously

document every aspect of the preparation process, including formulation, com-

pounding, packaging, and labeling procedures. These records serve to establish

traceability and accountability throughout the product’s life cycle, facilitating ef-

cient batch recall procedures if necessary. Additionally, they include comprehensive

reports of quality control tests, stability assessments, and records of adverse events,

S. Shilpi et al.

265

providing critical data for ongoing product monitoring and regulatory compliance.

Together, accurate labeling and thorough documentation play pivotal roles in main-

taining the integrity and safety of LVPs, ensuring they meet stringent regulatory

standards and are administered safely in clinical settings.

10.6 Conclusion

Parenteral admixtures are utilized to increase the therapeutic effectiveness, stability

of the product and maintain the nutritional and electrolyte balance in the body. It is

also used to reduce adverse effect of drugs. The regulatory authorities of different

countries regulate the manufacturing to assure the quality, stability, and microbio-

logical integrity of the parenteral admixture. Preparing parenteral admixtures

requires adherence to strict guidelines to prevent contamination, ensure sterility,

and maintain compatibility between ingredients. Pharmacists and healthcare profes-

sionals play a crucial role in preparing these admixtures safely and accurately, fol-

lowing established protocols and using aseptic techniques to minimize the risk of

complications for patients receiving these medications.

References

Aggett PJ (2012) Iron. In: Erdman JW, Macdonald IA, Zeisel SH (eds) Present knowledge in nutri-

tion, 10th edn. Wiley-Blackwell, Washington, DC, pp506–520

Ahmed TA, Khalid M, Ahmed OA, Zidan AS (2018) Sterile dosage forms loaded nanosystems

for parenteral, nasal, pulmonary and ocular administration. In: Nanoscale fabrication, optimi-

zation, scale-up and biological aspects of pharmaceutical nanotechnology. William Andrew

Publishing, pp335–395

Allen LV Jr (2021) Intravenous admixture preparation considerations, part 9-A: error prevention in

intravenous admixture preparation. Int J Pharm Compd 25(2):131–139

Anon (n.d.-a) A dynamic duo: the roles of calcium + vitamin D in the body. https://store.mayo-

clinic.com/education/the- roles- of- calcium- vitamin- d- in- the- body/. Accessed 15 Jul 2024

Anon (n.d.-b) Dietary supplements for immune function and infectious diseases—health pro-

fessional fact sheet. https://ods.od.nih.gov/factsheets/ImmuneFunction- HealthProfessional/.

Accessed 15 Jul 2024

Anon (n.d.-c) Vitamin D-NHS. https://www.nhs.uk/conditions/vitamins- and- minerals/vitamin- d/.

Accessed 15 Jul 2024

Assouline B, Faivre A, Verissimo T, Sangla F, Berchtold L, Giraud R, Bendjelid K, Sgardello S,

Elia N, Pugin J, De Seigneux S, Legouis D (2021) Thiamine, ascorbic acid, and hydrocortisone

as a metabolic resuscitation cocktail in sepsis: a meta-analysis of randomized controlled tri-

als with trial sequential analysis. Crit Care Med 49(12):2112–2120. https://doi.org/10.1097/

ccm.0000000000005262

Bakrey H, Shivgotra R, Abdu A, Soni B, Shahtaghia NR, Jain SK, Thakur S (2024) Use of total

parenteral nutrition (TPN) as a vehicle for drug delivery. Curr Drug Targets 25(5):306–329

Berger MM, Herter-Aeberli I, Zimmermann MB, Spieldenner J, Eggersdorfer M (2021)

Strengthening the immunity of the Swiss population with micronutrients: a narrative review

and call for action. Clin Nutr ESPEN 43:39–48. https://doi.org/10.1016/j.clnesp.2021.03.012

10 Sterile Products andAdmixtures

266

Blicharska E, Szczęsna B, Kocjan R, Gumieniczek A, Komsta Ł (2016) Analysis of dissolution

proles of iron, zinc, and manganese from complex dietary supplements by ion chromatogra-

phy and chemometrics. J Liq Chromatogr Relat Technol 39(1):30–34

Boullata JI, Gilbert K, Sacks G, Labossiere RJ, Crill C, Goday P, Kumpf VJ, Mattox TW, Plogsted

S, Holcombe B, American Society for Parenteral and Enteral Nutrition (2014) ASPEN clinical

guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing.

J Parenter Enter Nutr 38(3):334–377

Boullata JI, Mirtallo JM, Sacks GS, Salman G, Gura K, Canada T, Maguire A, ASPEN Parenteral

Nutrition Safety Committee (2022) Parenteral nutrition compatibility and stability: a compre-

hensive review. J Parenter Enter Nutr 46(2):273–299

Calder PC, Ortega EF, Meydani SN, Adkins Y, Stephensen CB, Thompson B, Zwickey H (2022)

Nutrition, immunosenescence, and infectious disease: an overview of the scientic evidence on

micronutrients and on modulation of the gut microbiota. Adv Nutr 13(5):S1–S26. https://doi.

org/10.1093/advances/nmac052

Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM (2017) Hypovitaminosis C

and vitamin C deciency in critically ill patients despite recommended enteral and parenteral

intakes. Crit Care 21(1):300. https://doi.org/10.1186/s13054- 017- 1891- y

Collins JF (2014) Copper. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR (eds)

Modern nutrition in health and disease, 11th edn. Lippincott Williams & Wilkins, Baltimore,

MD, pp206–216

Dehmel C, Braune SA, Kreymann G, Baehr M, Langebrake C, Hilgarth H, Nierhaus A, Dartsch

DC, Kluge S (2011 Aug) Do centrally pre-prepared solutions achieve more reliable drug con-

centrations than solutions prepared on the ward? Intensive Care Med 37:1311–1316

Desai NR, Shah SM, Koczone J, Vencl-Joncic M (2007) Zinc content of commercial diluents widely

used in drug admixtures prepared for intravenous infusion. Int J Pharm Compd 11(5):426

Dongare SD, Mali SS, Patrekar PV (2015) Sterile parenteral products: a narrative approach. J Drug

Deliv Ther 5(1):41–48

Driscoll DF, Bhargava HN, Li L, Zaim RH, Babayan VK, Bistrian BR (1995) Physicochemical

stability of total nutrient admixtures. Am J Health Syst Pharm 52:623

Driscoll DF, Bacon MN, Bistrian BR (2000) Physicochemical stability of two types of intravenous

lipid emulsion as total nutrient admixtures. J Parenter Enter Nutr 24(1):15–22

Eggersdorfer M, Berger MM, Calder PC, Gombart AF, Ho E, Laviano A, Meydani SN (2022)

Perspective: role of micronutrients and omega-3 long-chain polyunsaturated fatty acids for

immune outcomes of relevance to infections in older adults-a narrative review and call for action.

Adv Nutr (Bethesda, MD) 13(5):1415–1430. https://doi.org/10.1093/ADVANCES/NMAC058

Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ etal (2023) Advances in drug

delivery systems, challenges and future directions. Heliyon 9(6):e17488

Garcia J, Garg A, Song Y, Fotios A, Andersen C, Garg S (2018) Compatibility of intravenous

ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion. PLoS One

13(1):e0190577

Gostyńska A, Stawny M, Dettlaff K, Jelińska A (2019) The interactions between ciprooxacin and

parenteral nutrition admixtures. Pharmaceutics 12(1):27

Harraki B, Guiraud P, Rochat MH, Fussellier M, Favier A (1993) Inuence of copper, iron, and

zinc on the physicochemical properties of parenteral admixture. PDA J Pharm Sci Technol

47(5):199–204

Hedlund N, Beer I, Hoppe-Tichy T, Trbovich P (2017) Systematic evidence review of rates and

burden of harm of intravenous admixture drug preparation errors in healthcare settings. BMJ

Open 7(12):e015912

Hoyois A, Ballarin A, Thomas J, Lheureux O, Preiser JC, Coppens E, Perez-Bogerd S, Taton

O, Farine S, Van Ouytsel P, Arvanitakis M (2021) Nutrition evaluation and management of

critically ill patients with COVID-19 during post-intensive care rehabilitation. JPEN J Parenter

Enteral Nutr 45(6):1153–1163. https://doi.org/10.1002/jpen.2101

Hu Q, Ren H, Hong Z, Wang C, Zheng T, Ren Y, Chen K, Liu S, Wang G, Guosheng G, Xiuwen W,

Ren J (2020) Early enteral nutrition preserves intestinal barrier function through reducing the

S. Shilpi et al.

267

formation of neutrophil extracellular traps (NETs) in critically ill surgical patients. Oxidative

Med Cell Longev 2020:1. https://doi.org/10.1155/2020/8815655

Jessurun JG, Hunfeld NG, van Rosmalen J, van Dijk M, van den Bemt PM (2022) Prevalence and

determinants of intravenous admixture preparation errors: a prospective observational study in

a university hospital. Int J Clin Pharm 44(1):44–52

Johnson NT, Probert MR (2014) Vitamin C revisited. Crit Care 18(4):460. https://doi.org/10.1107/

s2053273316095346

Kapp RW (2018) Gastrointestinal tract as a major route of pharmaceutical administration. In:

Toxicology of the gastrointestinal tract, 2nd edn. CRC Press, CRC Press, pp113–149

Khalili H, Sheikhbabayi M, Samadi N, Jamalifar H, Dalili D, Samadi N (2013) Bacterial contami-

nation of single-and multiple-dose vials after multiple use and intravenous admixtures in three

different hospitals in Iran. Iran J Pharm Res 12(1):205

Lee ZY, Ortiz-Reyes L, Lew CCH, Shahnaz Hasan M, Ke L, Patel JJ, Stoppe C, Heyland DK

(2023) Intravenous vitamin C monotherapy in critically ill patients: a systematic review and

meta-analysis of randomized controlled trials with trial sequential analysis. Ann Intensive Care

13(1):1–17. https://doi.org/10.1186/S13613- 023- 01116- X/TABLES/3

Ludwig JD (2019) Parenteral dosage forms: introduction and historical perspective. In: Parenteral

medications, 4th edn. CRC Press, pp3–9

MacDonald RS (2000) The role of zinc in growth and cell proliferation. J Nutr 130(5):1500S–1508S

Manchanda S, Das N, Chandra A, Bandyopadhyay S, Chaurasia S (2020) Fabrication of advanced

parenteral drug-delivery systems. In: Drug delivery systems. Academic Press, pp47–84

Meyer BK, Ni A, Binghua H, Shi L (2007) Antimicrobial preservative use in parenteral products:

past and present. J Pharm Sci 96(12):3155–3167. https://doi.org/10.1002/jps.20976

Nema S, Brendel RJ (2016) Excipients for parenteral dosage forms: regulatory considerations and

controls. In: Pharmaceutical dosage forms-parenteral medications. CRC Press, pp123–148

Nema S, Brendel RJ, Washkuhn R (2007) Excipients: parenteral dosage forms and their role. In:

Encyclopedia of pharmaceutical technology. Informa Healthcare, NewYork, pp1622–1645

Nikam Nikita R, Vaishnavi A, Lalchand D (2023) Parenteral drug delivery approach: an overview.

Journal of Xidian Univ 17(1):386–400

Otero-Millán L, Bea-Mascato B, Legido Soto JL, Martínez-López-De-Castro N, Lago-Rivero

N (2024a) Evaluation of the stability of newborn hospital parenteral nutrition solutions.

Pharmaceutics 16(3):316

Otero-Millán L, Bea-Mascato B, Legido Soto JL, Martínez-López-De-Castro N, Lago-Rivero N

(2024b) Physicochemical stability of hospital parenteral nutrition solutions: effect of changes

in composition and storage protocol. Pharmaceutics 16(5):572

Pecora F, Persico F, Argentiero A, Neglia C, Esposito S (2020) The role of micronutrients in

support of the immune response against viral infections. Nutrients 12(10):1–45. https://doi.

org/10.3390/nu12103198

Piwowarczyk L, Tomczak S, Antkowiak P, Jelińska A, Stawny M (2022) Sodium valproate incom-

patibility with parenteral nutrition admixtures-a risk to patient safety: an invitro evaluation

study. Pharmaceutics 14(2):371

Pramanick S, Singodia D, Chandel V (2013) Excipient selection in parenteral formulation devel-

opment. Pharma Times 45(3):65–77

Preiser JC, Arabi YM, Berger MM, Casaer M, McClave S, Montejo-González JC, Peake S, Blaser

AR, Van den Berghe G, van Zanten A, Wernerman J, Wischmeyer P (2021) A guide to enteral

nutrition in intensive care units: 10 expert tips for the daily practice. Crit Care 25(1):1–13.

https://doi.org/10.1186/S13054- 021- 03847- 4/FIGURES/3

Rayaprolu BM, Strawser JJ, Anyarambhatla G (2018) Excipients in parenteral formulations: selec-

tion considerations and effective utilization with small molecules and biologics. Drug Dev Ind

Pharm 44(10):1565–1571

Riera P, Garrido-Alejos G, Cardenete J, Moliner E, Zapico-Muñiz E, Cardona D, Garin N (2018)

Physicochemical stability and sterility of standard parenteral nutrition solutions and simulated

Y-site admixtures for neonates. Nutr Clin Pract 33(5):694–700

10 Sterile Products andAdmixtures

268

Serventi L, Keeling I, Harris A, Craig A, Adams MR, Bi Y, Ruan J, Ham EE, Broad TM, Smith

GT, Blackman HL, Liu Z, Mullally SA, Mohajer M, Mehta A, Feng Z (2023) Water soluble

vitamins. In: Sustainable development goals series part F2751. Springer, pp91–106. https://

doi.org/10.1007/978- 3- 031- 12358- 0_7

Stawny M, Gostyńska A, Dettlaff K, Jelińska A, Kościelniak M, Ogrodowczyk M (2019)

Development, validation, and stability assessment application of RP-HPLC-DAD method for

quantication of ampicillin in total parenteral nutrition admixtures. Antibiotics 8(4):268

Tomczak S, Stawny M, Jelińska A (2020) Co-administration of drugs and parenteral nutrition:

in vitro compatibility studies of loop diuretics for safer clinical practice. Pharmaceutics

12(11):1092

Tomczak S, Chmielewski M, Szkudlarek J, Jelińska A (2023) Antiemetic drugs compatibility eval-

uation with paediatric parenteral nutrition admixtures. Pharmaceutics 15(8):2143

Tubic-Grozdanis M, Krämer I (2015) Parenteral. In: Practical pharmaceutics. Springer, pp265–299.

https://doi.org/10.1007/978- 3- 319- 15814- 3_13

Tubic-Grozdanis M, Krämer I (2023) Parenteral. In: Practical pharmaceutics: an interna-

tional guideline for the preparation, care and use of medicinal products, 2nd edn. Springer,

pp473–519. https://doi.org/10.1007/978- 3- 031- 20298- 8_21

Watrobska-Swietlikowska D (2019) Compatibility of maximum inorganic and organic calcium

and phosphate content in neonatal parenteral solutions. Sci Rep 9(1):10525

Wijaya CH, Wijaya W, Mehta BM (2015) General properties of minor food components. In:

Handbook of food chemistry, pp55–74. https://doi.org/10.1007/978- 3- 642- 36605- 5_40

Yeo KS, Kua SW, Teoh GS, Onsiong MK (2001) The use of thiopentone/propofol admixture for

laryngeal mask airway insertion. Anaesth Intensive Care 29(1):38–42

S. Shilpi et al.

269

Challenges andAdvances

inPharmaceutical Development

ofTopical andTransdermal Dosage

Forms

JaspreetKaur, Manju, AmanjotKaur, MonuYadav,

NehaRaina, SumitKumar, AkhileshKumar,

andMadhuGupta

Abstract

This chapter explores the challenges and advances in the pharmaceutical devel-

opment of topical and transdermal dosage forms. It discusses key formulation

challenges, including drug stability, solubility, skin permeation, and irritation.

The chapter highlights advances in skin permeation enhancement techniques,

such as the use of chemical enhancers, physical methods, and vesicular systems.

J. Kaur

University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies (UGC-

CAS), Panjab University, Chandigarh, India

Rayat Institute of Pharmacy, Ropar, Punjab, India

Manju

University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies (UGC-

CAS), Panjab University, Chandigarh, India

A. Kaur

Rayat Institute of Pharmacy, Ropar, Punjab, India

M. Yadav (

Amity Institute of Pharmacy, Amity University, Haryana, Amity Education Valley Gurugram,

Manesar, Panchgaon, Haryana, India

N. Raina · M. Gupta (

Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University,

New Delhi, India

S. Kumar

Department of Pharmaceutical Sciences, Central University Haryana, Mahendragarh, India

A. Kumar

Division of Medicine, ICAR-Indian Veterinary Research Institute,

Bareilly, Uttar Pradesh, India

<<< < Предыдущая 16 17 18 19 20 21 22 23 24 25 26 2728 / 4528 29 30 31 32 33 34 35 36 37 38 39 40 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
10.10.202610 Мб0Книга_5434_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.202610 Мб0Книга_5435_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_5436_Библиотеки_им_академика_М_И_Перельмана.pdf
#
29.08.202685 Мб0Книга_544_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_5440_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_5441_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_5442_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_5443_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20269 Мб0Книга_5444_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20268 Мб0Книга_5445_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20268 Мб0Книга_5446_Библиотеки_им_академика_М_И_Перельмана.pdf